Showing results (751-760 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|February 5, 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trialThomas Walter, Astrid Lievre, Romain Coriat, et al.
The Lancet. Oncology|March 3, 2023
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trialMarc-Oliver Grimm, Christine Barbara Grün, Günter Niegisch, et al.
The Lancet. Oncology|August 11, 2022
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry studySabine R de Wild, Linda de Munck, Janine M Simons, et al.
The Lancet. Oncology|February 4, 2023
Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trialVratislav Strnad, Csaba Polgár, Oliver J Ott, et al.
The Lancet. Oncology|November 18, 2022
Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based studyLaura Botta, Gemma Gatta, Riccardo Capocaccia, et al.
The Lancet. Oncology|March 6, 2025
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trialNicholas Zdenkowski, Marion J J Kuper-Hommel, Samuel M Niman, et al.
The Lancet. Oncology|February 20, 2025
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trialHervé Bonnefoi, Florence Lerebours, Marina Pulido, et al.
The Lancet. Oncology|February 20, 2025
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 studyGeorgina V Long, Victoria Atkinson, Serigne N Lo, et al.
The Lancet. Oncology|January 23, 2025
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trialSusan van der Lei, Robbert S Puijk, Madelon Dijkstra, et al.
The Lancet. Oncology|November 14, 2024
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysisLuca Mastrantoni, Marta Chiaravalli, Alexia Spring, et al.
Pageof 336